Breast Implant-Makers Now Required To File Individual Reports On Each Adverse Event, FDA Says
Executive Summary
The agency is redoubling efforts to warn women about the risks of silicone and saline breast implants after feedback from a recent advisory panel meeting. On 2 May, the regulator said it is requiring manufacturers to file individual Medical Device Reports for each adverse event regarding implants – part of a bigger effort to end its Alternative Summary Reporting Program for all devices.
You may also be interested in...
Australia Set To Decide On Breast Implant Cancer Link; Dutch Say No To A Ban
Australian regulators expect to say in a few weeks’ time what action, if any, they will take on breast implants following the ongoing worldwide reports of a link between certain types of product and a rare form of cancer. Meanwhile, authorities in the Netherlands say the implants can stay on the market.
FDA Quietly Sunsetting Summary Reporting Program For Adverse Events, Readies Public Release Of Millions Of Pre-2017 Summarized MDR Reports
The US FDA expects to turn the lights out on its 22-year-old Alternative Summary Reporting Program for adverse events at the end of May, the agency tells Medtech Insight. But it's the FDA's upcoming online release of millions of summarized Medical Device Reports sent to the agency between 1998 and 2017 that could have the tongues of industry – and the public – wagging.
France Bans Breast Implants Linked To Rare Cancer; Canada Close Behind
There is now enough safety evidence to merit withdrawing macro-textured and polyurethane-coated breast implants from the market, according to health product regulators in France and Canada.